← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Buffalo Biolabs, Llc
Buffalo, NY
$3,724,662
Total funding
11
Grants
Funding over time
peak $1.5M · FY2009–17$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$3,724,662 · 11
By mechanism
N44$1,496,764 · 1
R43$1,044,914 · 4
R41$684,272 · 3
N43$498,712 · 3
Investigators at Buffalo Biolabs, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
TAS::75 0849::TAS SBIR TOPIC 255 PHASE II DEVELOPMENT OF ANTICANCER AGENTS$1,496,764
N44 · FY2011 · CA
Testing of novel anti-cancer compounds Curaxins against pancreatic cancer$300,000
R41 · FY2012 · CA
A Novel TLR5 Agonist-Based Adjuvant for Poliovirus Vaccine$293,169
R43 · FY2017 · AI
A Novel TLR5 Agonist-Based Adjuvant for Poliovirus Vaccine$288,029
R43 · FY2016 · AI
Deimmunized TLR5 Agonist for Anticancer Therapy$223,303
R43 · FY2014 · CA
Protectan CBLB502 for the improvement of head and neck cancer radiation therapy$200,000
N43 · FY2012 · CA
Testing of novel anti-cancer compounds Curaxins against pancreatic cancer$179,664
R41 · FY2013 · CA
PHYSICAL SCIENCES (BASIC)$149,987
N43 · FY2009 · CA
BIOMEDICAL (BASIC)$148,725
N43 · FY2009 · CA
Targeting MLL As Anticancer Therapy for Infant Acute Lymphoblastic Leukemia$130,694
R43 · FY2009 · CA
Generation of a Monoclonal Antibody Agonist to Toll-Like Receptor 5$109,719
R43 · FY2009 · CA
Safety/Efficacy of Liposomal Reversan, a novel MRP1 modulator for Cancer Therapy$104,608
R41 · FY2009 · CA
Suv39H Targeted Therapy for Treatment of Childhood Rhabdomyosarcoma$100,000
R41 · FY2012 · CA